Who is sponsoring NCT03645746?

NCT03645746 is sponsored by Regeneron Pharmaceuticals.

What condition does NCT03645746 study?

NCT03645746 studies Healthy Volunteer.

What drugs are being tested in NCT03645746?

Interventions: REGN5069, Placebo.

What is the status of NCT03645746?

NCT03645746 is currently COMPLETED.

Last reviewed 2019-11-26 · How we verify

Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers

NCT03645746 PHASE1 COMPLETED

The primary objective of the study is to evaluate the safety and tolerability of single ascending doses of REGN5069 administered intravenously (IV) and subcutaneously (SC) in healthy male and female participants. The secondary objectives of the study are to characterize the pharmacokinetics (PK) profile of single IV and SC doses of REGN5069 in healthy participants and assess the immunogenicity of REGN5069 in healthy participants administered single IV or SC doses of REGN5069

Details

Lead sponsor	Regeneron Pharmaceuticals
Phase	PHASE1
Status	COMPLETED
Enrolment	56
Start date	Thu Aug 23 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Sep 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Healthy Volunteer

Interventions

REGN5069
Placebo

Countries

Belgium